Stay updated on Avutometinib Alone vs Combo in Low-Grade Serous Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Avutometinib Alone vs Combo in Low-Grade Serous Ovarian Cancer Clinical Trial page.

Latest updates to the Avutometinib Alone vs Combo in Low-Grade Serous Ovarian Cancer Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check9 days agoChange DetectedThe web page has removed two studies related to Avutometinib (VS-6766) and Defactinib in the context of recurrent low-grade serous ovarian cancer, indicating a significant update in the content.SummaryDifference0.3%
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check45 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study descriptions and inclusion criteria for a clinical trial on Low-Grade Serous Ovarian Cancer, while adding references to the study's collaborators and a new version revision number.SummaryDifference14%
- Check53 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for January 29, 2025. However, the deletion of the date March 25, 2025, does not significantly impact the core content.SummaryDifference0.4%
- Check60 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
Stay in the know with updates to Avutometinib Alone vs Combo in Low-Grade Serous Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Avutometinib Alone vs Combo in Low-Grade Serous Ovarian Cancer Clinical Trial page.